Last week, from 5 to 9 March, the groundbreaking series of Alzheimer’s and Parkinson’s disease (AD/PD 2024) conferences took place in Lisbon, at Centro de Congressos de Lisboa.
AD/PD™ works towards advancing innovative strategies in therapy, prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing a better future for patients and families affected by neurodegenerative diseases.
WG5 leader, Inês Figueira, was present at AD/PD to broadcast IMMUPARKNET COST Action and the importance to study immune response in Parkinson’s disease progression to researchers, clinicians and stakeholders in the field.
